Nevertheless, treatment with anti-PD-1 and PD-L1 can lead to immune-related adverse events, which may include diarrhea, colitis, pancreatitis, as well as neurological, hematological, and pneumonitis-related complications.[6] Moreover, prolonged treatment may trigger severe immune reactions. This evidence concerns the gene CD274 and colitis.